Maturation-based model of arrhythmogenic right ventricular dysplasia using patient-specific induced pluripotent stem cells

Circulation Journal

Volumn 79, Issue 7, 2015, Pages 1402-1408

  Wen, Jian Yan ^a,b   Wei, Chuan Yu ^b   Shah, Khooshbu ^b   Wong, Johnson ^b   Wang, Cheng ^b   Chen, Huei Sheng Vincent ^b,c  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Fatty acid oxidation; Induced pluripotent stem cell derived cardiomyocytes; Metabolic maturation; Peroxisome proliferator activated receptor ; Reactive oxygen species

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PKP2 PROTEIN, HUMAN; PLAKOPHILIN;

ADULT; BIOLOGICAL MODEL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL DIFFERENTIATION; DESMOSOME; GENETICS; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MUTATION; NUCLEAR REPROGRAMMING; PATHOLOGY;

ADULT; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CELL DIFFERENTIATION; CELLS, CULTURED; CELLULAR REPROGRAMMING; DESMOSOMES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, CARDIOVASCULAR; MUTATION; MYOCYTES, CARDIAC; PLAKOPHILINS; PPAR ALPHA; PPAR GAMMA;

EID: 84934325794     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0363     Document Type: Article

References (54)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: A report from the American Heart Association. Circulation 2014; 129: e28-e292, doi:10.1161/01.cir.0000441139.02102.80.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
4. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
5. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair: Ready for the next step. Circulation 2006; 114: 339-352.
6. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008; 28: 208-216.
7. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: Observations on stem cells and cardiac repair. J Am Coll Cardiol 2006; 47: 1777-1785.
8. Chen HS, Kim C, Mercola M. Electrophysiological challenges of cell-based myocardial repair. Circulation 2009; 120: 2496-2508.
9. Carvajal-Vergara X, Sevilla A, D’Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derivedmodels of LEOPARD syndrome. Nature 2010; 465: 808-812.
10. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363: 1397-1409.
11. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-229.
12. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
13. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2012; 4: 180-191.
14. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012; 4: 130ra147, doi:10.1126/scitranslmed.3003552.
15. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12: 101-113.
16. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013; 494: 105-110.
17. Sinnecker D, Goedel A, Laugwitz KL, Moretti A. Induced pluripotent stem cell-derived cardiomyocytes: A versatile tool for arrhythmia research. Circ Res 2013; 112: 961-968.
18. Mercola M, Colas A, Willems E. Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res 2013; 112: 534-548.
19. Knollmann BC. Induced pluripotent stem cell-derived cardiomyocytes: Boutique science or valuable arrhythmia model? Circ Res 2013; 112: 969-976, discussion 976.
20. Santostefano KE, Hamazaki T, Biel NM, Jin S, Umezawa A, Terada N. A practical guide to induced pluripotent stem cell research using patient samples. Lab Invest 2015; 95: 4-13.
21. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: A report of 24 adult cases. Circulation 1982; 65: 384-398.
22. Calkins H, Marcus F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: An update. Curr Cardiol Rep 2008; 10: 367-375.
23. den Haan AD, Tan BY, Zikusoka MN, Llado LI, Jain R, Daly A, et al. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet 2009; 2: 428-435.
24. Awad MM, Calkins H, Judge DP. Mechanisms of disease: Molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008; 5: 258-267.
25. Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol 2012; 9: 223-233.
26. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria. Circulation 2010; 121: 1533-1541.
27. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, et al. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116: 2012-2021.
28. Asimaki A, Tandri H, Huang H, Halushka MK, Gautam S, Basso C, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009; 360: 1075-1084.
29. Basso C, Pilichou K, Thiene G. Is it time for plakoglobin immunehistochemical diagnostic test for arrhythmogenic cardiomyopathy in the routine pathology practice? Cardiovasc Pathol 2013; 22: 312-313.
30. Li D, Liu Y, Maruyama M, Zhu W, Chen H, Zhang W, et al. Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Hum Mol Genet 2011; 20: 4582-4596.
31. Swope D, Cheng L, Gao E, Li J, Radice GL. Loss of cadherinbinding proteins beta-catenin and plakoglobin in the heart leads to gap junction remodeling and arrhythmogenesis. Mol Cell Biol 2012; 32: 1056-1067.
32. Zhang Z, Stroud MJ, Zhang J, Fang X, Ouyang K, Kimura K, et al. Normalization of Naxos plakoglobin levels restores cardiac function in mice. J Clin Invest 2015; 125: 1708-1712.
33. Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ. The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res 2014; 114: 454-468.
34. Lombardi R, Dong J, Rodriguez G, Bell A, Leung TK, Schwartz RJ, et al. Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2009; 104: 1076-1084.
35. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferatoractivated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
36. Brasaemle DL. Thematic review series: Adipocyte biology. The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets and control of lipolysis. J Lipid Res 2007; 48: 2547-2559.
37. Awad MM, Dalal D, Tichnell C, James C, Tucker A, Abraham T, et al. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum Mutat 2006; 27: 1157.
38. Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113: 1641-1649.
39. Onay-Besikci A. Regulation of cardiac energy metabolism in newborn. Mol Cell Biochem 2006; 287: 1-11.
40. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90: 207-258.
41. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: Fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008; 197: 189-204.
42. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
43. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, et al. Identification of a physiologically relevant endogenous ligand for PPARα in liver. Cell 2009; 138: 476-488.
44. Razani B, Zhang H, Schulze PC, Schilling JD, Verbsky J, Lodhi IJ, et al. Fatty acid synthase modulates homeostatic responses to myocardial stress. J Biol Chem 2011; 286: 30949-30961.
45. Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, Coirault C. A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res 2009; 84: 83-90.
46. γ leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791-2801.
47. γ individually responds to serotoninand fatty acid-metabolites. EMBO J 2010; 29: 3395-3407.
48. Cerrone M, Lin X, Zhang M, Agullo-Pascual E, Pfenniger A, Chkourko Gusky H, et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation 2014; 129: 1092-1103.
49. Ferrick DA, Neilson A, Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008; 13: 268-274.
50. Neubauer S. The failing heart: An engine out of fuel. N Engl J Med 2007; 356: 1140-1151.
51. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: The renaissance cell. Circ Res 2009; 105: 1164-1176.
52. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 2014; 20: 616-623.
53. Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, et al. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med 2014; 6: 240ra274, doi:10.1126/scitranslmed.3008008.
54. Noorman M, Hakim S, Kessler E, Groeneweg JA, Cox MG, Asimaki A, et al. Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathy. Heart Rhythm 2013; 10: 412-419.